Serafin Morales Murillo

Martin, M; Zielinski, C; Ruiz-Borrego, M; Carrasco, E; Ciruelos, E; Munoz, M; Bermejo, B; Margeli, M; Turner, N; Casas, M; Anton, A; Csoszi, T; Corsaro, M; Murillo, L; Morales, S; Alba, E; Bartlett, CH; Koehler, M; Guerrero, A; Kahan, Z; Gil-Gil, M

Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006): A phase 3 trial of Palbociclib (PAL) in combination with endocrine therapy (ET) versus Capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (MBC) patients (pts) whose disease progressed on aromatase inhibitors (AIs)

CANCER RESEARCH 80 -. 01/02/2020.

[doi:10.1158/1538-7445.SABCS19-GS2-07]

Braso-Maristany, F; Griguolo, G; Pascual, T; Pare, L; Nuciforo, P; Llombart-Cussac, A; Bermejo, B; Oliveira, M; Morales, S; Martinez, N; Vidal, M; Adamo, B; Martinez, O; Pernas, S; Lopez, R; Muñoz M; Chic, N; Galvan, P; Garau, I; Manso, L; Alarcon, J; Martinez, E; Gregorio, S; Gomis, RR; Villagrasa, P; Cortes, J; Ciruelos, E; Prat, A

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade.

Nature Communications 11 385-385. 20/01/2020.

[doi:10.1038/s41467-019-14111-3]

Quintela-Fandino, M; Morales, S; Cortes-Salgado, A; Manso, L; Apala, JV; Munoz, M; Cudos, AG; Fortuny, JS; Gion, M; Lopez-Alonso, A; Cortes, J; Guerra, J; Malon, D; Caleiras, E; Mulero, F; Mouron, S

Randomized Phase O/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer

CLINICAL CANCER RESEARCH 26 35-45. 01/01/2020.

[doi:10.1158/1078-0432.CCR-19-2023]

Prat, A; Pascual, T; De Angelis, C; Gutierrez, C; Llombart-Cussac, A; Wang, T; Cortes, J; Rexer, B; Pare, L; Forero, A; Wolff, AC; Morales, S; Adamo, B; Braso-Maristany, F; Vidal, M; Veeraraghavan, J; Krop, I; Galvan, P; Pavlick, AC; Bermejo, B; Izquierdo, M; Rodrik-Outmezguine, V; Reis-Filho, JS; Hilsenbeck, SG; Oliveira, M; Dieci, MV; Griguolo, G; Fasani, R; Nuciforo, P; Parker, JS; Conte, P; Schiff, R; Guarneri, V; Osborne, CK; Rimawi, MF

HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE 112 46-54. 01/01/2020.

[doi:10.1093/jnci/djz042]

MORALES MURILLO, SERAFIN

Clinical Benefit with Palbociclib in Estrogen Receptor-Positive, Her2-Negative Metastatic Breast Cancer: New Concepts

Clinics of Oncology 2 -. 20/11/2019.

Ciruelos, EM; Diaz, MN; Isla, MD; Lopez, R; Bernabe, R; Gonzalez, E; Cirauqui, B; Coves, J; Morales, S; Arcediano, A; Barneto, I; Cerezuela, P; Illarramendi, JJ; Morales, C; Ponce, S

Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer

EUROPEAN JOURNAL OF CANCER CARE 28 -. 01/11/2019.

[doi:10.1111/ecc.13164]

Aapro, M; Ruiz-Borrego, M; Hegg, R; Kukielka-Budny, B; Morales, S; Cinieri, S; Freitas, R; Garcia-Estevez, L; Szombara, E; Borges, GS; Passalacqua, R; Hervieu, H; Groc, M; Villanova, G

Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor-positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial)

BREAST 45 7-14. 01/06/2019.

[doi:10.1016/j.breast.2019.01.009]

Pascual, T; Martin, M; Fernandez-Martinez, A; Pare, L; Alba, E; Rodriguez-Lescure, A; Perrone, G; Cortes, J; Morales, S; Lluch, A; Urruticoechea, A; Gonzalez-Farre, B; Galvan, P; Jares, P; Rodriguez, A; Chic, N; Righi, D; Cejalvo, JM; Tonini, G; Adamo, B; Vidal, M; Villagrasa, P; Muñoz M; Prat, A

A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

Frontiers in oncology 9 303-303. 26/04/2019.

[doi:10.3389/fonc.2019.00303]

MORALES MURILLO, SERAFIN; GASOL CUDOS, ARIADNA; VEAS RODRIGUEZ, JOEL; SANTACANA ESPASA, MARIA; MELE OLIVE, JORDI; CANOSA MORALES, CARLOS; IGLESIAS MARTINEZ, EDELMIRO

Vitamin D as A Prognostic Factor in Triple Negative Breast Cancer

Annals of Cancer Therapy and Pharmacology 2 1-8. 15/04/2019.

Blancas, I; Aguirre, E; Morales, S; Gonzalvez, ML; Servitja, S; Diaz, N; del Barco, S; Barnadas, A; Margeli, M; García Carbonero I; Llombart, A

Real-world data on the efficacy and safety of weekly oral vinorelbine in breast cancer patients previously treated with anthracycline or taxane-based regimens

CLINICAL & TRANSLATIONAL ONCOLOGY 21 459-466. 01/04/2019.

[doi:10.1007/s12094-018-1946-9]

MORALES MURILLO, SERAFIN; GASOL CUDOS, ARIADNA; VELASCO SANCHEZ, ANA; MARTINEZ ORTIN, DAVID; SALLA FORTUNY, JOEL; TEJERO NARBONA, RUBEN; SERRATE LOPEZ, ANNA ALBA; VILARDELL VILLELLAS, FELIPE; SALUD SALVIA, ANTONIA

Clinical and Biological Factors Associated with ISH Amplification in HER2 2+ by IHC in Breast Cancer Patients

Biomedical Journal of Scientific & Technical Research -. 28/03/2019.

[doi:10.26717/BJSTR.2019.16.002860]

Gavila, J; Oliveira, M; Pascual, T; Perez-Garcia, J; Gonzàlez X; Canes, J; Pare, L; Calvo, I; Ciruelos, E; Muñoz M; Virizuela, JA; Ruiz, I; Andres, R; Perello, A; Martinez, J; Morales, S; Marin-Aguilera, M; Martinez, D; Quero, JC; Llombart-Cussac, A; Prat, A

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

BMC MEDICINE 17 8-8. 09/01/2019.

[doi:10.1186/s12916-018-1233-1]